CHAMPIONS ONCOLOGY INC (CSBR) Fundamental Analysis & Valuation

NASDAQ:CSBR • US15870P3073

Current stock price

5.99 USD
+0.03 (+0.5%)
Last:

This CSBR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CSBR Profitability Analysis

1.1 Basic Checks

  • In the past year CSBR has reported negative net income.
  • CSBR had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: CSBR reported negative net income in multiple years.
  • In multiple years CSBR reported negative operating cash flow during the last 5 years.
CSBR Yearly Net Income VS EBIT VS OCF VS FCFCSBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

  • CSBR has a Return On Assets (-8.02%) which is in line with its industry peers.
  • With a Return On Equity value of -53.28%, CSBR is not doing good in the industry: 70.18% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -8.02%
ROE -53.28%
ROIC N/A
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSBR Yearly ROA, ROE, ROICCSBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

  • In the last couple of years the Profit Margin of CSBR has grown nicely.
  • In the last couple of years the Operating Margin of CSBR has grown nicely.
  • CSBR has a Gross Margin (45.88%) which is in line with its industry peers.
  • CSBR's Gross Margin has been stable in the last couple of years.
  • CSBR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.88%
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
CSBR Yearly Profit, Operating, Gross MarginsCSBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CSBR Health Analysis

2.1 Basic Checks

  • CSBR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CSBR has more shares outstanding than it did 1 year ago.
  • CSBR has more shares outstanding than it did 5 years ago.
  • CSBR has a worse debt/assets ratio than last year.
CSBR Yearly Shares OutstandingCSBR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
CSBR Yearly Total Debt VS Total AssetsCSBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • CSBR has an Altman-Z score of -0.13. This is a bad value and indicates that CSBR is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -0.13, CSBR is not doing good in the industry: 71.93% of the companies in the same industry are doing better.
  • The Debt to FCF ratio of CSBR is 0.03, which is an excellent value as it means it would take CSBR, only 0.03 years of fcf income to pay off all of its debts.
  • CSBR has a better Debt to FCF ratio (0.03) than 94.74% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that CSBR is not too dependend on debt financing.
  • CSBR's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. CSBR outperforms 70.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z -0.13
ROIC/WACCN/A
WACC10.99%
CSBR Yearly LT Debt VS Equity VS FCFCSBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • CSBR has a Current Ratio of 0.98. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.98, CSBR is doing worse than 89.47% of the companies in the same industry.
  • CSBR has a Quick Ratio of 0.98. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CSBR's Quick ratio of 0.98 is on the low side compared to the rest of the industry. CSBR is outperformed by 84.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
CSBR Yearly Current Assets VS Current LiabilitesCSBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CSBR Growth Analysis

3.1 Past

  • CSBR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -109.43%.
  • The Earnings Per Share has been growing by 146.62% on average over the past years. This is a very strong growth
  • CSBR shows a decrease in Revenue. In the last year, the revenue decreased by -1.10%.
  • The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)-109.43%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-105.56%
Revenue 1Y (TTM)-1.1%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-2.81%

3.2 Future

  • CSBR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -52.39% yearly.
  • Based on estimates for the next years, CSBR will show a quite strong growth in Revenue. The Revenue will grow by 18.26% on average per year.
EPS Next Y-72.8%
EPS Next 2Y-52.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.41%
Revenue Next 2Y7.38%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CSBR Yearly Revenue VS EstimatesCSBR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M 100M
CSBR Yearly EPS VS EstimatesCSBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. CSBR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CSBR. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 58.73, CSBR can be considered very expensive at the moment.
  • CSBR's Price/Forward Earnings is on the same level as the industry average.
  • CSBR is valuated expensively when we compare the Price/Forward Earnings ratio to 21.41, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 58.73
CSBR Price Earnings VS Forward Price EarningsCSBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CSBR indicates a somewhat cheap valuation: CSBR is cheaper than 77.19% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 21.8
EV/EBITDA N/A
CSBR Per share dataCSBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • CSBR's earnings are expected to decrease with -52.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.39%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CSBR Dividend Analysis

5.1 Amount

  • No dividends for CSBR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CSBR Fundamentals: All Metrics, Ratios and Statistics

CHAMPIONS ONCOLOGY INC

NASDAQ:CSBR (5/1/2026, 8:19:17 PM)

5.99

+0.03 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Industry Strength22.36
Industry Growth50.93
Earnings (Last)03-12
Earnings (Next)07-21
Inst Owners48.14%
Inst Owner Change0.62%
Ins Owners26.48%
Ins Owner Change0%
Market Cap83.20M
Revenue(TTM)57.94M
Net Income(TTM)-2.28M
Analysts82.86
Price Target12.24 (104.34%)
Short Float %0.81%
Short Ratio10.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.85%
Min EPS beat(2)-121.79%
Max EPS beat(2)96.08%
EPS beat(4)3
Avg EPS beat(4)84.01%
Min EPS beat(4)-121.79%
Max EPS beat(4)296.08%
EPS beat(8)7
Avg EPS beat(8)615.16%
EPS beat(12)8
Avg EPS beat(12)388.53%
EPS beat(16)9
Avg EPS beat(16)240.28%
Revenue beat(2)1
Avg Revenue beat(2)1.37%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)5.01%
Revenue beat(4)3
Avg Revenue beat(4)1.28%
Min Revenue beat(4)-2.27%
Max Revenue beat(4)5.01%
Revenue beat(8)7
Avg Revenue beat(8)5.99%
Revenue beat(12)7
Avg Revenue beat(12)1.47%
Revenue beat(16)9
Avg Revenue beat(16)0.99%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 58.73
P/S 1.44
P/FCF 21.8
P/OCF 18.94
P/B 19.43
P/tB 21.07
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)0.1
Fwd EY1.7%
FCF(TTM)0.27
FCFY4.59%
OCF(TTM)0.32
OCFY5.28%
SpS4.17
BVpS0.31
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -8.02%
ROE -53.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.88%
FCFM 6.59%
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score4
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA N/A
Cap/Depr 39.86%
Cap/Sales 1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z -0.13
F-Score4
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-109.43%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-105.56%
EPS Next Y-72.8%
EPS Next 2Y-52.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.1%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-2.81%
Revenue Next Year3.41%
Revenue Next 2Y7.38%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y-133.06%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-50.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y156.8%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y187.69%
OCF growth 3Y4.35%
OCF growth 5Y20.48%

CHAMPIONS ONCOLOGY INC / CSBR Fundamental Analysis FAQ

What is the fundamental rating for CSBR stock?

ChartMill assigns a fundamental rating of 3 / 10 to CSBR.


What is the valuation status of CHAMPIONS ONCOLOGY INC (CSBR) stock?

ChartMill assigns a valuation rating of 2 / 10 to CHAMPIONS ONCOLOGY INC (CSBR). This can be considered as Overvalued.


How profitable is CHAMPIONS ONCOLOGY INC (CSBR) stock?

CHAMPIONS ONCOLOGY INC (CSBR) has a profitability rating of 3 / 10.